| Year |
Citation |
Score |
| 2024 |
Stoff R, Markovic SN, McWilliams RR, Kottschade LA, Montane HN, Dimou A, Dudek AZ, Tan W, Dronca RS, Seetharam M, Chen R, Block MS. Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting. Melanoma Research. PMID 39207855 DOI: 10.1097/CMR.0000000000000997 |
0.305 |
|
| 2021 |
Kankeu Fonkoua LA, Chakrabarti S, Sonbol MB, Kasi PM, Starr JS, Liu AJ, Nevala WK, Maus RL, Bois MC, Pitot HC, Chandrasekharan C, Ross HJ, Wu TT, Graham RP, Villasboas JC, ... ... Markovic SN, et al. Outcomes on anti-VEGFR-2/paclitaxel treatment following progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. International Journal of Cancer. PMID 33739449 DOI: 10.1002/ijc.33559 |
0.331 |
|
| 2021 |
Mansfield AS, Nevala WK, Lieser EA, Leontovich AA, Markovic SN. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology. 2: e24436. PMID 23762809 DOI: 10.4161/onci.24436 |
0.341 |
|
| 2020 |
Vera Aguilera J, Paludo J, McWilliams RR, Zhang H, Li Y, Kumar AB, Failing J, Kottschade LA, Block MS, Markovic SN, Dong H, Dronca RS, Yan Y. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Research. PMID 32404734 DOI: 10.1200/Jco.2018.36.15_Suppl.9558 |
0.438 |
|
| 2020 |
Kotwal A, Rouleau SG, Kottschade L, Ryder MM, Kudva YC, Markovic S, Erickson DZ. OR32-02 Immune Checkpoint Inhibitor-Induced Hypophysitis Is Associated with Improved Overall Survival in Cancer Patients Journal of the Endocrine Society. 4. DOI: 10.1210/Jendso/Bvaa046.869 |
0.347 |
|
| 2020 |
Javed A, Saleh ASA, Block MS, McWilliams RR, Yan Y, Kottschade LA, Markovic S. Patterns of hepato-pulmonary metastasis and their impact on clinical outcomes in uveal melanoma. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E22052 |
0.323 |
|
| 2020 |
Block MS, Suman VJ, Nevala WK, Finnes HD, Schimke J, Strand C, Dimou A, Kottschade LA, Yan Y, Reid JM, Hocum C, Markovic S, McWilliams RR. A phase I trial of nab-paclitaxel/bevacizumab (AB160) nano-immunoconjugate therapy for unresectable stage IV malignant melanoma (MM): MC1371 (NCT02020707). Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E22020 |
0.355 |
|
| 2020 |
Maus RL, Leontovich A, Moore R, Nevala WK, Flotte TJ, Geyer S, Guo R, Schimke J, Dicke BA, Markovic S. Utilizing quantitative multiplex immunofluorescence to characterize paracrine interactions within the tumor-immune landscape of metastatic melanoma. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E15184 |
0.389 |
|
| 2020 |
Fonkoua LAK, Chakrabarti S, Sonbol MB, Kasi PM, Starr JS, Liu AJ, Bois MC, Pitot HC, Chandrasekharan C, Ross HJ, Wu T, Graham RP, Markovic S, Dong H, Yoon HH. Enhanced efficacy of anti-VEGFR2/taxane therapy after progression on immune checkpoint inhibition (ICI) in patients (pts) with metastatic gastroesophageal adenocarcinoma (mGEA). Journal of Clinical Oncology. 38: 4541-4541. DOI: 10.1200/Jco.2020.38.15_Suppl.4541 |
0.359 |
|
| 2020 |
Slingluff CL, Blumenstein BA, Lewis KD, Andtbacka RHI, Hyngstrom JR, Milhem MM, Markovic S, Hamid O, Hernandez-Aya LF, Bowles TL, Philips P, Jang S, Lutzky J, Bar A, Beitsch PD. Final analysis of relapse-free survival in a multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine after resection of high-risk melanoma. Journal of Clinical Oncology. 38: 10017-10017. DOI: 10.1200/Jco.2020.38.15_Suppl.10017 |
0.315 |
|
| 2020 |
Vera J, Paludo J, Kottschade L, Block M, Yan Y, Loprinzi C, Markovic S. Abstract B15: Dabrafenib-trametinib-induced pyrexia successfully treated with colchicine Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Ras18-B15 |
0.368 |
|
| 2019 |
Kazemi NY, Jain C, Bois MC, Behfar A, Olivier K, Markovic SN. Heart Block Caused by Cardiac Metastasis From Merkel Cell Carcinoma: A Case Report. Mayo Clinic Proceedings. Innovations, Quality & Outcomes. 3: 510-516. PMID 31993571 DOI: 10.1016/J.Mayocpiqo.2019.09.005 |
0.492 |
|
| 2019 |
Daneshmand A, Goyal G, Markovic S, Zekeridou A, Wijdicks EFM, Hocker SE. Autoimmune Encephalitis Secondary to Melanoma. Annals of Internal Medicine. PMID 30743260 DOI: 10.7326/L18-0593 |
0.304 |
|
| 2019 |
Aguilera JV, Flotte TJ, Yi ES, Kroneman T, Suman V, Paludo J, McWilliams RR, Kottschade LA, Yan Y, Block MS, Markovic S. Quantitative assessment of tumor-infiltrating neutrophils to predict immunotherapy responses in metastatic melanoma. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E21039 |
0.309 |
|
| 2019 |
Aguilera JV, Erskine CL, Suman VJ, Paludo J, McWilliams RR, Kottschade LA, Yan Y, Dronca RS, Dong H, Markovic S, Block MS. IL-12p40 and MIP3a to predict clinical responses to anti-PD-1 therapy in patients with metastatic melanoma. Journal of Clinical Oncology. 37: 9535-9535. DOI: 10.1200/Jco.2019.37.15_Suppl.9535 |
0.351 |
|
| 2019 |
Yang F, Wang Y, Nowakowski GS, Wang M, Chintakuntlawar AV, Halfdanarson TR, Pagliaro LC, Wei J, Liu B, Molina JR, Markovic S. Association of sex, age and ECOG performance status with cancer immunotherapy efficacy in randomized controlled trials. Journal of Clinical Oncology. 37: 6592-6592. DOI: 10.1200/Jco.2019.37.15_Suppl.6592 |
0.318 |
|
| 2019 |
Yan Y, Dong H, Dronca R, Markovic S. Abstract PR11: CX3CR1+CD8+ T-cells are responsible to the clinical benefit of chemoimmunotherapy in metastatic melanoma patients after disease progression on PD-1 blockade Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Pr11 |
0.444 |
|
| 2018 |
Aguilera JV, Paludo J, Tschautscher M, Yu C, Duma N, Markovic S. A clinical insight into therapeutic sequence in advanced melanoma. Journal of Clinical Oncology. 36: 186-186. DOI: 10.1200/Jco.2018.36.5_Suppl.186 |
0.366 |
|
| 2018 |
Dronca RS, Mansfield A, Liu X, Harrington S, Enninga E, Markovic S, Kottschade L, Mcwilliams R, Block M, Nevala W, Thompson M, Dong H. Abstract A38: Blood-based T cell biomarkers and soluble PD-L1 predict responses and immune-related toxicity to PD-1 blockade in melanoma and lung cancer Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A38 |
0.39 |
|
| 2018 |
Vera-Aguilera J, Paludo J, Duma N, Tschautscher M, Yu C, Markovic S. Abstract LB-A32: A clinical insight into therapeutic sequence in advanced melanoma Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-A32 |
0.368 |
|
| 2017 |
Youland RS, Blanchard ML, Dronca R, Kottschade L, Markovic SN, Olivier KR, Park SS. Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era. Clinical and Translational Radiation Oncology. 6: 25-30. PMID 29594220 DOI: 10.1016/J.Ctro.2017.09.002 |
0.542 |
|
| 2017 |
Youland RS, Packard AT, Blanchard MJ, Arnett AL, Wiseman GA, Kottschade LA, Dronca RS, Markovic SN, Olivier KR, Park SS. 18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma. Advances in Radiation Oncology. 2: 204-210. PMID 28740933 DOI: 10.1016/J.Adro.2017.02.003 |
0.506 |
|
| 2017 |
Yan Y, Dronca RS, Liu X, Markovic S, Dong H. Effect of paclitaxel and carboplatin on tumor-reactive T cells and the efficacy of PD-1 blockade. Journal of Clinical Oncology. 35: 65-65. DOI: 10.1200/Jco.2017.35.7_Suppl.65 |
0.411 |
|
| 2017 |
Dronca RS, Harrington S, Jegapragasan M, Kottschade LA, Nevala WK, Enninga EA, Markovic S, Dong H. Association of soluble PD-L1 (sPD-L1) with decreased survival in metastatic melanoma. Journal of Clinical Oncology. 35: 4-4. DOI: 10.1200/Jco.2017.35.7_Suppl.4 |
0.345 |
|
| 2017 |
Majithia N, Manana AV, Yan Y, Kottschade LA, Dronca RS, Block MS, Nevala WK, Markovic S. The prognostic role of preoperative serum lactate dehydrogenase (LDH) in patients with resected advanced melanoma. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E21054 |
0.379 |
|
| 2017 |
Markovic S, Galli F, Suman VJ, Nevala WK, Paulsen AM, Hung JC, Gansen DN, Erickson LA, Marchetti P, Wiseman GA, Signore A. Non-invasive clinical visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: A pilot study. Journal of Clinical Oncology. 35: 3034-3034. DOI: 10.1200/Jco.2017.35.15_Suppl.3034 |
0.395 |
|
| 2017 |
Dronca RS, Mansfield AS, Liu X, Harrington S, Enninga EA, Kottschade LA, Koo CW, McWilliams RR, Block MS, Nevala WK, Markovic S, Dong H. Bim and soluble PD-L1 (sPD-L1) as predictive biomarkers of response to anti-PD-1 therapy in patients with melanoma and lung carcinoma. Journal of Clinical Oncology. 35: 11534-11534. DOI: 10.1200/Jco.2017.35.15_Suppl.11534 |
0.305 |
|
| 2017 |
Harris AL, Thompson M, Markovic S, Durham W, Dawson L, Small D, Copland JA. Abstract LB-130: Tumor regression in novel triple therapy BRAF mutant metastatic melanoma patient-derived preclinical models Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-130 |
0.425 |
|
| 2017 |
Thanarajasingam U, Pinkston O, Kottschade L, Finnes H, Markovic S. SAT0711 Checkpoint inhibitor therapy in patients with advanced malignancies and preexisting rheumatologic disease: the mayo clinic experience Annals of the Rheumatic Diseases. 76: 1044-1044. DOI: 10.1136/Annrheumdis-2017-Eular.5461 |
0.421 |
|
| 2016 |
Towns JN, Dripps L, Jenkins S, Lackore K, Yost KJ, Ristow K, Colgan J, Habermann TM, Inwards DJ, Johnston PB, Klebig R, Lin Y, Markovic S, Micallef IN, Nowakowski GS, et al. Impact of lymphoma survivorship clinic visit on patient-centered outcomes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 64. PMID 28151205 DOI: 10.1200/Jco.2016.34.3_Suppl.64 |
0.302 |
|
| 2016 |
Leontovich AA, Dronca RS, Nevala WK, Thompson MA, Kottschade LA, Ivanov LV, Markovic SN. Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients. Melanoma Research. PMID 27824739 DOI: 10.1097/CMR.0000000000000290 |
0.329 |
|
| 2016 |
Failing JJ, Finnes HD, Kottschade LA, Allred JB, Markovic SN. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma. Melanoma Research. PMID 27603551 DOI: 10.1200/Jco.2016.34.15_Suppl.E21038 |
0.354 |
|
| 2016 |
Rule WG, Allred JB, Pockaj BA, Markovic SN, DiCaudo DJ, Erickson LA, Deming RL, Schild SE. Results of NCCTG N0275 (Alliance) - a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma. Cancer Medicine. PMID 27368067 DOI: 10.1002/cam4.783 |
0.323 |
|
| 2016 |
Kottschade L, Brys A, Peikert T, Ryder M, Raffals L, Brewer J, Mosca P, Markovic S. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Research. 26: 469-80. PMID 27306502 DOI: 10.1097/Cmr.0000000000000273 |
0.305 |
|
| 2016 |
Kwek SS, Kahn J, Greaney SK, Lewis J, Cha E, Zhang L, Weber RW, Leonard L, Markovic SN, Fong L, Spitler LE. GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses. Oncoimmunology. 5: e1101204. PMID 27141383 DOI: 10.1080/2162402X.2015.1101204 |
0.311 |
|
| 2016 |
Kottschade LA, McWilliams RR, Markovic SN, Block MS, Villasboas Bisneto J, Pham AQ, Esplin BL, Dronca RS. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Research. PMID 26848796 DOI: 10.1200/Jco.2015.33.15_Suppl.9010 |
0.441 |
|
| 2016 |
Yan Y, Failing J, Leontovich AA, Block MS, McWilliams RR, Kottschade LA, Dronca RS, Markovic S. The Mayo Clinic experience in patients with metastatic melanoma who have failed previous pembrolizumab treatment. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E21014 |
0.385 |
|
| 2016 |
Sabol AJ, Markovic S, Otley C, Price KAR. Benefit of chemotherapy (CT) in patients (pts) with Merkel cell carcinoma (MCC) with distant metastases (mets) and visceral organ involvement. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E21000 |
0.325 |
|
| 2016 |
Nowakowski GS, Ansell SM, Witzig TE, Macon WR, Ristow K, Colgan J, Inwards DJ, Johnston PB, Klebig R, Lin Y, Micallef INM, Markovic S, Porrata LF, Thompson CA, Habermann TM. Participation in clinical trials to improve outcomes of patients with relapsed lymphoma. Journal of Clinical Oncology. 34: 7523-7523. DOI: 10.1200/Jco.2016.34.15_Suppl.7523 |
0.338 |
|
| 2015 |
Blanchard M, Shim KG, Grams MP, Rajani K, Diaz RM, Furutani KM, Thompson J, Olivier KR, Park SS, Markovic SN, Pandha H, Melcher A, Harrington K, Zaidi S, Vile R. Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy. International Journal of Radiation Oncology, Biology, Physics. 93: 577-87. PMID 26461000 DOI: 10.1016/J.Ijrobp.2015.07.2274 |
0.543 |
|
| 2015 |
Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN. Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation. Journal of Hematology & Oncology. 8: 80. PMID 26138828 DOI: 10.1200/Jco.2015.33.15_Suppl.E19500 |
0.359 |
|
| 2015 |
Witzig TE, Reeder C, Han JJ, LaPlant B, Stenson M, Tun HW, Macon W, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic S, et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 126: 328-35. PMID 25921059 DOI: 10.1182/Blood-2015-02-629543 |
0.366 |
|
| 2015 |
Moser JC, Pulido JS, Dronca RS, McWilliams RR, Markovic SN, Mansfield AS. The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma Melanoma Research. 25: 59-63. PMID 25396683 DOI: 10.1097/CMR.0000000000000125 |
0.314 |
|
| 2015 |
Shreders A, Joseph RW, Johnson DB, Peng C, Puzanov I, Dronca RS, Bryce AH, Markovic S, Kottschade LA, Sosman JA. Early change in lactate dehydrogenase is marker of response to PD-1/PDL1 inhibitors. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E20045 |
0.325 |
|
| 2015 |
White ML, Atwell TD, Kurup AN, Schmit G, Carter R, Geske J, Kottschade LA, Block MS, Callstrom MR, Markovic S. Recurrence and survival outcomes following percutaneous thermal ablation of oligometastatic melanoma. Journal of Clinical Oncology. 33: e20040-e20040. DOI: 10.1200/Jco.2015.33.15_Suppl.E20040 |
0.368 |
|
| 2015 |
Leon-Ferre RA, Kottschade LA, Lowe VJ, Markovic S. Utility of PET/CT for surveillance of asymptomatic patients with resected stage III or IV melanoma. Journal of Clinical Oncology. 33: 9051-9051. DOI: 10.1200/Jco.2015.33.15_Suppl.9051 |
0.321 |
|
| 2015 |
Dronca RS, Markovic S, Kottschade LA, McWilliams RR, Block MS, Nevala WK, Thompson MA, Dong H. Bim as a predictive T-cell biomarker for response to anti-PD-1 therapy in metastatic melanoma (MM). Journal of Clinical Oncology. 33: 9013-9013. DOI: 10.1200/Jco.2015.33.15_Suppl.9013 |
0.375 |
|
| 2015 |
Dronca R, Liu X, Lisa K, Mcwilliams R, Markovic S, Dong H. Bim and PD-1 identify effector CD8 T cells responsive to anti-PD-1 therapy in metastatic melanoma patients Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P298 |
0.359 |
|
| 2015 |
Porrata L, Ristow K, McPhail ED, Macon W, Maurer MJ, Nowakowski GS, Ansell S, Witzig TE, Markovic S, Habermann TM. Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma Blood. 126: 3885-3885. DOI: 10.1182/Blood.V126.23.3885.3885 |
0.327 |
|
| 2015 |
Harris AL, Marlow L, Mathias A, Dawson L, Durham W, Meshaw K, Mullin R, Small D, Synnott A, Wu K, Milosevic D, Netzel B, Grebe S, Markovic S, Copland J. Abstract 2417: Characterization of novel patient derived melanoma xenografts and cell lines in response to targeted therapies Cancer Research. 75: 2417-2417. DOI: 10.1158/1538-7445.Am2015-2417 |
0.398 |
|
| 2015 |
Lin Y, Atwell T, Weisbrod A, Maas M, Armstrong A, Deeds M, Bulur P, Gustafson M, Zhang Z, Cordes S, Porrata L, Markovic S, Johnston P, Micallef I, Inwards D, et al. Dendritic cell vaccine treatment for indolent B-cell non-Hodgkin lymphoma: clinical trial in progress Cytotherapy. 17: S17. DOI: 10.1016/J.Jcyt.2015.03.358 |
0.302 |
|
| 2015 |
Youland R, Blanchard M, Markovic S, Olivier K, Park S. A Comparison of Stereotactic Body Radiation Therapy (SBRT) Versus Conventional/Hypofractionated Radiation Therapy (CHRT) for Metastatic Malignant Melanoma (MM) International Journal of Radiation Oncology*Biology*Physics. 93: E629-E630. DOI: 10.1016/J.Ijrobp.2015.07.2154 |
0.509 |
|
| 2014 |
Suciu S, Eggermont AM, Lorigan P, Kirkwood J, Markovic S, Garbe C, Cameron D, Kotapati S, Konto C, Chen T, Wheatley K, Ives N, De Schaetzen G, Efendi A, Buyse M. 1089PDRELAPSE-FREE SURVIVAL (RFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN ADJUVANT INTERFERON TRIALS IN PATIENTS (PTS) WITH RESECTABLE CUTANEOUS MELANOMA: AN INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv376. PMID 28171156 DOI: 10.1093/Annonc/Mdu344.5 |
0.316 |
|
| 2014 |
Moser J, Pulido J, Dronca RS, Markovic S, Mansfield AS. The Mayo Clinic experience with the use of kinase inhibitors (KIs), ipilimumab, and bevacizumab in the treatment of metastatic ocular melanoma. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E20011 |
0.397 |
|
| 2014 |
Suciu S, Ives N, Eggermont AM, Kirkwood JM, Lorigan P, Markovic S, Garbe C, Wheatley K. Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): An individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts). Journal of Clinical Oncology. 32: 9067-9067. DOI: 10.1200/Jco.2014.32.15_Suppl.9067 |
0.334 |
|
| 2014 |
Dong H, Zhao W, Krco CJ, Markovic S, Mansfield AS, Olivier KR, Park SS, Kwon ED. A novel method for identifying downstream signals in tumor-reactive T cells following PD-1 engagement and monitoring endogenous tumor immunity and immunotherapy. Journal of Clinical Oncology. 32: 3049-3049. DOI: 10.1200/Jco.2014.32.15_Suppl.3049 |
0.559 |
|
| 2014 |
Lin Y, Atwell T, Weisbrod A, Maas M, Armstrong A, Deeds M, Bulur P, Gustafson M, Zhang Z, Porrata L, Markovic S, Johnston P, Micallef I, Inwards D, Colgan J, et al. Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P76 |
0.316 |
|
| 2014 |
Felice KMD, Markovic S, Kottschade LA, Finnes HD, Loftus EV, Raffals LH. Mo1273 Ipilimumab-Induced Colitis in Patients With Metastatic Melanoma Gastroenterology. 146. DOI: 10.1016/S0016-5085(14)62188-0 |
0.369 |
|
| 2014 |
Park SS, Dong H, Zhao W, Grams MP, Liu X, Harrington SM, Furutani KM, Krco CJ, Olivier KR, Markovic SN, Kwon ED. PD-1 Blockade Enhances Radiation Therapy-Induced Abscopal Effect International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.05.201 |
0.494 |
|
| 2013 |
Barney BM, Markovic SN, Laack NN, Miller RC, Sarkaria JN, Macdonald OK, Bauer HJ, Olivier KR. Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT). International Journal of Radiation Oncology, Biology, Physics. 87: 73-80. PMID 23920388 DOI: 10.1016/J.Ijrobp.2013.05.012 |
0.548 |
|
| 2013 |
Agostino NM, Weiss M, Shi W, Nevala WK, Hemperly S, Markovic S, Nair SG. A prospective evaluation of vascular endothelial growth factor (VEGF) and the immune system in stage III/IV melanoma. Journal of Clinical Oncology. 31: e20046-e20046. DOI: 10.1200/Jco.2013.31.15_Suppl.E20046 |
0.352 |
|
| 2013 |
Velazquez AI, Markovic S, Inwards DJ, Micallef INM, Johnston PB, Hogan WJ, Ansell SM, Porrata LF. Day 100 peripheral blood absolute monocyte/lymphocyte count prognostic score and survival in diffuse large B-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation. Journal of Clinical Oncology. 31: 7041-7041. DOI: 10.1200/Jco.2013.31.15_Suppl.7041 |
0.349 |
|
| 2013 |
Dong H, Markovic S, Krco CJ, Kwon ED. A novel method to identify and monitor endogenous tumor-reactive T cells by high expression of CD11a (LFA-1) and PD-1 (CD279) as immunologic readout for evaluating the efficacy of PD-1 blockade. Journal of Clinical Oncology. 31: 3037-3037. DOI: 10.1200/Jco.2013.31.15_Suppl.3037 |
0.374 |
|
| 2013 |
Janco J, Markovic S, Weaver A, Cliby W. Preoperative chemotherapy for vulvar and vaginal melanoma Gynecologic Oncology. 131: 278. DOI: 10.1016/J.Ygyno.2013.04.029 |
0.353 |
|
| 2012 |
Finn L, Markovic SN, Joseph RW. Therapy for metastatic melanoma: the past, present, and future. Bmc Medicine. 10: 23. PMID 22385436 DOI: 10.1186/1741-7015-10-23 |
0.305 |
|
| 2012 |
Mansfield AS, Nevala WK, Markovic S. Immunomodulatory effects of bevacizumab in metastatic malignant melanoma. Journal of Clinical Oncology. 30: 82-82. DOI: 10.1200/Jco.2012.30.30_Suppl.82 |
0.425 |
|
| 2012 |
Mansfield AS, Nevala WK, Markovic S. Immunologic changes in patients with metastatic melanoma on bevacizumab and chemotherapy versus chemotherapy alone. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E21112 |
0.413 |
|
| 2012 |
Barney BM, Markovic S, Laack NN, Miller RC, Sarkaria JN, Macdonald OK, Olivier KR. Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGF-i) following stereotactic body radiotherapy (SBRT). Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E14507 |
0.556 |
|
| 2012 |
Rochet NM, Porrata LF, Kottschade LA, Grotz TE, Markovic S. Preoperative peripheral blood lymphocyte/monocyte ratio and survival in patients with resected stage IV melanoma. Journal of Clinical Oncology. 30: 8600-8600. DOI: 10.1200/Jco.2012.30.15_Suppl.8600 |
0.35 |
|
| 2011 |
Markovic S, Burch PA, LaPlant B, Heun JM, Bradshaw R. Adjuvant GM-CSF therapy for patients with resected stage III/IV melanoma: A retrospective review of a single-center experience. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8596. PMID 28020960 DOI: 10.1200/Jco.2011.29.15_Suppl.8596 |
0.372 |
|
| 2011 |
Barney B, Olivier K, Wilson Z, Miller R, Macdonald O, Brown P, Foote R, Markovic S. Clinical Outcomes and Toxicity using Stereotactic Body Radiotherapy (SBRT) for Stage IV Melanoma International Journal of Radiation Oncology*Biology*Physics. 81: S687. DOI: 10.1016/J.Ijrobp.2011.06.959 |
0.499 |
|
| 2010 |
Croghan GA, Suman VJ, Maples WJ, Albertini M, Linette G, Flaherty L, Eckardt J, Ma C, Markovic SN, Erlichman C. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study. Cancer. 116: 3463-8. PMID 20564112 DOI: 10.1002/cncr.25191 |
0.3 |
|
| 2010 |
Nowakowski GS, Ristow K, Kurtin P, Allen MS, Micallef IN, Colgan J, Inwards DJ, McPhail E, Markovic S, Ansell SM, Porrata L, Johnston PB, Thompson CA, Witzig TE, Habermann TM. Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes – Single Institution Experience Blood. 116: 4168-4168. DOI: 10.1182/Blood.V116.21.4168.4168 |
0.378 |
|
| 2010 |
Maurer MJ, Cerhan J, Katzmann JA, Link B, Micallef IN, Colgan J, Habermann TM, Inwards DJ, Markovic S, Ansell SM, Porrata L, Johnston PB, Nowakowski GS, Thompson CA, Gupta M, et al. Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival Blood. 116: 4136-4136. DOI: 10.1182/Blood.V116.21.4136.4136 |
0.366 |
|
| 2010 |
Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef I, Johnston PB, Colgan J, Nowakowski GS, Witzig TE, Ansell SM, Markovic S, Porrata L. The Absolute Monocyte and Lymphocyte Counts at Diagnosis Predict Survival and Identify High-Risk Patients In Diffuse Large-B-Cell Lymphoma Blood. 116: 3088-3088. DOI: 10.1182/Blood.V116.21.3088.3088 |
0.378 |
|
| 2010 |
Witzig TE, Hui T, Micallef IN, Ansell SM, Link B, Inwards DJ, Porrata L, Johnston PB, Colgan J, Markovic S, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Weiner G, et al. A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas Blood. 116: 287-287. DOI: 10.1182/Blood.V116.21.287.287 |
0.406 |
|
| 2009 |
Sekulic A, Miller A, Barrett M, Ejadi S, Mengos A, Pockaj B, Markovic S. Identification of targetable cellular subsets within melanoma tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 9082. PMID 27962203 DOI: 10.1200/Jco.2009.27.15_Suppl.9082 |
0.321 |
|
| 2009 |
Mansfield AS, Markovic SN. Novel therapeutics for the treatment of metastatic melanoma. Future Oncology (London, England). 5: 543-57. PMID 19450181 DOI: 10.2217/fon.09.15 |
0.302 |
|
| 2009 |
Porrata L, Inwards DJ, Ansell SM, Micallef I, Johnston PL, Hogan W, Markovic S. Absolute Lymphocyte Count Assessed During Routine Follow-up Is a Risk Factor for Relapse Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma. Blood. 114: 4359-4359. DOI: 10.1182/Blood.V114.22.4359.4359 |
0.346 |
|
| 2009 |
Gendler S, Pathangey L, Lakshminarayanan V, Mukherjee P, Pockaj B, Suman V, Loserth L, Markovic S, Ingle J. Examination of Immune Competence in Breast Cancer Patients at Six Months Post Surgery and Adjuvant Therapy through Assessment of T Cell and Dendritic Cell Functionality. Cancer Research. 69: 4131-4131. DOI: 10.1158/0008-5472.Sabcs-09-4131 |
0.385 |
|
| 2008 |
Markovic SN, Suman VJ, Nevala WK, Geeraerts L, Creagan ET, Erickson LA, Rowland KM, Morton RF, Horvath WL, Pittelkow MR. A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study. American Journal of Clinical Oncology. 31: 573-9. PMID 19060590 DOI: 10.1097/COC.0b013e318173a536 |
0.315 |
|
| 2008 |
McWilliams RR, Rao RD, Buckner JC, Link MJ, Markovic S, Brown PD. Melanoma-induced brain metastases. Expert Review of Anticancer Therapy. 8: 743-55. PMID 18471047 DOI: 10.1586/14737140.8.5.743 |
0.354 |
|
| 2007 |
Olivier KR, Schild SE, Morris CG, Brown PO, Markovic SN. A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma Cancer. 110: 1791-1795. PMID 17721993 DOI: 10.1002/Cncr.22988 |
0.55 |
|
| 2007 |
Katipamula R, Ristow K, Colgan JP, Habermann TM, Johnston PB, Inwards DJ, Markovic SN, Micallef IN, Porrata LF, White WL, Witzig TE, Ansell SM. Primary Diffuse Large B-Cell Lymphoma of the Colon: Surgery for Local Disease Control Does Not Improve Outcome. Blood. 110: 3444-3444. DOI: 10.1182/BLOOD.V110.11.3444.3444 |
0.312 |
|
| 2007 |
Reeder CB, Gornet MK, Habermann TM, Ansell SM, Micallef IN, Porrata LF, Johnston PB, Maurer MJ, LaPlant B, Kabat B, Inwards DJ, Colgan JP, Call T, Markovic S, Zent CS, et al. A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL). Blood. 110: 121-121. DOI: 10.1182/Blood.V110.11.121.121 |
0.39 |
|
| 2006 |
Rao RD, Windschitl HE, Allred JB, Lowe VJ, Maples WJ, Gornet MK, Suman VJ, Creagan ET, Pitot HC, Markovic SN. Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma Journal of Clinical Oncology. 24: 8043-8043. DOI: 10.1200/JCO.2006.24.18_SUPPL.8043 |
0.324 |
|
| 2006 |
Behl D, Markovic SN, Witzig TE, Colgan JP, Habermann TM, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Porrata LF. Absolute lymphocyte count prior to rituximab therapy predicts time to progression in patients with follicular grade 1 lymphoma Journal of Clinical Oncology. 24: 7586-7586. DOI: 10.1200/JCO.2006.24.18_SUPPL.7586 |
0.315 |
|
| 2006 |
Joao C, Geyer S, Markovic S, Gertz M, Lacy M, Dispenzieri A, Kumar S, Hayman S, Gastineau D, Porrata L. Recovery of polyclonal immunoglobulin serum levels to normal levels after autologous stem cell transplantation predicts disease free survival in patients with multiple myeloma Journal of Clinical Oncology. 24: 10088-10088. DOI: 10.1200/Jco.2006.24.18_Suppl.10088 |
0.353 |
|
| 2005 |
Dietz AB, Markovic S, Greiner C, Maas M, Butler G, Bulur P, Suman V, Allred J, Vuk-Pavlovic S. Immunotherapy of malignant melanoma using a dendritic cell-amplified tumor RNA vaccine: A phase I study Journal of Clinical Oncology. 23: 2597-2597. DOI: 10.1200/Jco.2005.23.16_Suppl.2597 |
0.359 |
|
| 2005 |
Joao C, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, Markovic SN. Early Lymphocyte Recovery after Autologous Stem Cell Transplantation Predicts Superior Survival in Mantle Cell Lymphoma. Blood. 106: 5466-5466. DOI: 10.1182/BLOOD.V106.11.5466.5466 |
0.306 |
|
| 2005 |
Nowakowski GS, Kaur P, Macon WR, Habermann TM, Ristow K, Ansell SM, Witzig TE, Markovic SN, Porrata LF, Micallef IN, Johnston PB, Colgan JP, Inwards DJ. Prognostic Factors and Survival of Patients with Primary Mediastinal Large B-Cell Lymphoma. Blood. 106: 4698-4698. DOI: 10.1182/BLOOD.V106.11.4698.4698 |
0.32 |
|
| 2002 |
Markovic S, Suman VJ, Dalton RJ, Woods JE, Fitzgibbons RJ, Wold LE, Buckner JC, Kugler JW, Mailliard JA, Rowland KM, Krook JE, Brown DW, Tirona MT, Creagan ET. Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (Megace) in selected patients with malignant melanoma. American Journal of Clinical Oncology. 25: 552-6. PMID 12477996 DOI: 10.1097/00000421-200212000-00003 |
0.382 |
|
| 2002 |
Markovic SN, Suman VJ, Vukov AM, Fitch TR, Hillman DW, Adjei AA, Alberts SR, Kaur JS, Braich TA, Leitch JM, Creagan ET. Phase II trial of KW2189 in patients with advanced malignant melanoma. American Journal of Clinical Oncology. 25: 308-12. PMID 12040295 DOI: 10.1097/00000421-200206000-00022 |
0.302 |
|
| Show low-probability matches. |